|
Dr. Uday Saxena is the Chief Scientific Officer of the Company, and has been the President and CEO of Reddy US Therapeutics, Inc. a Dr. Reddy's subsidiary since 2002. Reddy US Therapeutics, Inc. is located in Atlanta, Georgia and is engaged in drug discovery in the areas of diabetes, inflammation and cardiovascular disease. Uday has been in the pharmaceutical/biotech industry for over a decade.
From 1997 to early 2000, Uday was Vice-President of Research, a corporate officer and a member of the executive committee at AtheroGenics, Inc, a publicly traded biopharmaceutical company located in Alpharetta, Georgia. While at AtheroGenics, he directed several drug discovery and early development programs that led to identification of novel compounds currently in late phase clinical trails for restenosis, atherosclerosis and chronic inflammation. Prior to that he was at the Parke-Davis Research Division in Ann Arbor, Michigan, where he was responsible for setting up a discovery program in inflammation and atherogenesis.
Uday has been an invited speaker at several national and international meetings and has also coordinated an International Conference on HDL metabolism in 1999. He is currently on the editorial board of two drug discovery-related journals and routinely reviews articles for research journals. He has been an elected fellow of the Council on Arteriosclerosis of the American Heart Association since 1991. He has over 50 full publications in peer-reviewed journals and invited review articles. He is an inventor, with several patents to his credit related to cardiovascular disease and inflammation. He also holds an adjunct faculty position in the Department of Physiology, University of Oklahoma, Health Sciences Center. Uday obtained his PhD from the Memorial University of Newfoundland in Canada and was a post-doctoral fellow at Columbia University, New York. | 